Revenue of top 20 neurology products in the U.S. 2016

This statistic displays the projected top 20 products for neurology diseases based on revenue in the United States during 2016. In that year, Abilify, an Otsuka product, is expected to generate approximately 322 million U.S. dollars in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.

Top 20 neurology products in the U.S. based on revenue in 2016 (in million U.S. dollars)*

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

October 2016

Region

United States

Survey time period

as of October 2016

Supplementary notes

* All values are projected. The original list inlcudes products FDA indicates as approved for treatimg MS, Parkinson's disease, Alzheimer's disease, depression, schizophrenia, bipolar and insomnia.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Top pharmaceutical drugs"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.